Carisma Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US14216R1014
USD
0.04
0 (0.51%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
45.25
0.00
3.73
3.65
3.38
9.20
3.40
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
45.25
0.00
3.73
3.65
3.38
9.20
3.40
Raw Material Cost
0.00
0.36
1.54
0.67
0.74
0.26
1.69
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.82
1.23
7.88
5.96
6.54
7.69
8.28
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
1.24
3.00
2.37
5.26
4.47
5.30
3.75
Other Expenses
-0.06
0.12
0.13
0.96
0.48
0.76
0.92
Total Expenditure (Excl Depreciation)
1.44
5.78
13.06
21.51
16.53
20.87
22.91
Operating Profit (PBDIT) excl Other Income
43.8
-5.8
-9.3
-17.9
-13.100000000000001
-11.7
-19.5
Other Income
0.90
-3.07
0.07
0.22
0.44
0.51
0.53
Operating Profit (PBDIT)
44.72
-8.49
-7.73
-16.97
-11.96
-10.91
-17.29
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Exceptional Items
0.00
-0.93
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
0.00
-0.36
2.19
2.98
2.65
8.94
1.70
Depreciation
0.00
0.36
1.54
0.67
0.74
0.26
1.69
Profit Before Tax
44.72
-9.77
-9.27
-17.64
-12.70
-11.16
-18.98
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
44.72
-9.77
-9.27
-17.64
-12.70
-11.16
-18.98
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
44.72
-9.77
-9.27
-17.64
-12.70
-11.16
-18.98
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
44.72
-9.77
-9.27
-17.64
-12.70
-11.16
-18.98
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
-0.87
-46.01
-36.66
-27.91
-11.13
0.36
10.89
Earnings per share (EPS)
1.07
-0.23
-0.22
-0.42
-0.31
-0.27
-0.46
Diluted Earnings per share
1.07
-0.23
-0.22
-0.42
-0.31
-0.27
-0.46
Operating Profit Margin (Excl OI)
96.83%
0.0%
-250.31%
-488.78%
-388.3%
-126.89%
-574.33%
Gross Profit Margin
98.82%
0.0%
-207.24%
-464.44%
-353.47%
-118.59%
-508.83%
PAT Margin
98.82%
0.0%
-248.48%
-482.75%
-375.24%
-121.37%
-558.67%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Sep 2025 is 1,232.35% vs -10.53% in Sep 2024

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Sep 2025 is 451.97% vs 40.65% in Sep 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2025 is 453.23% vs 42.59% in Sep 2024

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024

Compare Quarterly Results Of Carisma Therapeutics, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
45.25
0.00
45.25
Other Operating Income
0.00
0.00
0.00
Total Operating income
45.25
0.00
45.25
Raw Material Cost
0.00
0.81
-0.81
-100.00%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.82
0.00
0.82
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
1.24
5.90
-4.66
-78.98%
Other Expenses
-0.06
1.94
-2.00
-103.09%
Total Expenditure (Excl Depreciation)
1.44
26.08
-24.64
-94.48%
Operating Profit (PBDIT) excl Other Income
43.81
-26.08
69.89
267.98%
Other Income
0.90
4.07
-3.17
-77.89%
Operating Profit (PBDIT)
44.72
-21.20
65.92
310.94%
Interest
0.00
0.00
0.00
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
0.00
-0.81
0.81
100.00%
Depreciation
0.00
0.81
-0.81
-100.00%
Profit Before Tax
44.72
-22.02
66.74
303.09%
Tax
0.00
0.00
0.00
Provisions and contingencies
0
0
0.00
Profit After Tax
44.72
-22.02
66.74
303.09%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
44.72
-22.02
66.74
303.09%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
44.72
-22.02
66.74
303.09%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
-0.87
273.25
-274.12
-100.32%
Earnings per share (EPS)
1.07
-1.05
2.12
201.90%
Diluted Earnings per share
1.07
-1.05
2.12
201.90%
Operating Profit Margin (Excl OI)
96.83%
0.00%
0.00
96.83%
Gross Profit Margin
98.82%
0.00%
0.00
98.82%
PAT Margin
98.82%
0.00%
0.00
98.82%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 4.53 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 0.00% vs -100.00% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 1,232.35% vs -10.53% in Sep 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 4.47 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 556.12% vs -5.38% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 451.97% vs 40.65% in Sep 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 4.38 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 911.11% vs 30.77% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 453.23% vs 42.59% in Sep 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 96.83%
in Sep 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024